Cubist Systematic Strategies’s Amylyx Pharmaceuticals AMLX Stock Holding History

Cubist Systematic Strategies’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$76.1K	Sell	5,603 -117,639	-95%	-$1.11M	﹤0.01%	2811
2025 Q2	$790K	Buy	123,242 +40,112	+48%	+$195K	﹤0.01%	2063
2025 Q1	$294K	Sell	83,130 -389,267	-82%	-$1.39M	﹤0.01%	2386
2024 Q4	$1.79M	Buy	472,397 +423,316	+862%	+$1.99M	0.01%	1427
2024 Q3	$159K	Sell	49,081 -117,467	-71%	-$264K	﹤0.01%	2622
2024 Q2	$316K	Sell	166,548 -9,566	-5%	-$18.5K	﹤0.01%	2332
2024 Q1	$500K	Sell	176,114 -260,721	-60%	-$3.41M	﹤0.01%	2603
2023 Q4	$6.43M	Buy	436,835 +236,645	+118%	+$3.63M	0.04%	714
2023 Q3	$3.67M	Buy	200,190 +145,942	+269%	+$3.09M	0.03%	952
2023 Q2	$1.17M	Sell	54,248 -9,750	-15%	-$263K	0.01%	1862
2023 Q1	$1.88M	Buy	63,998 +60,192	+1,582%	+$2.09M	0.01%	1720
2022 Q4	$141K	Sell	3,806 -298	-7%	-$10.6K	﹤0.01%	3717
2022 Q3	$116K	Sell	4,104 -48,896	-92%	-$1.22M	﹤0.01%	3972
2022 Q2	$1.02M	Buy	53,000 +18,086	+52%	+$215K	0.01%	2469
2022 Q1	$449K	Buy	+34,914	New	+$789K	﹤0.01%	2603

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cubist Systematic Strategies's AMLX Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Amylyx Pharmaceuticals (AMLX) stake by 95% in Q3 2025, selling an estimated $1.11M and leaving 5,603 shares worth $76.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2811.

Cubist Systematic Strategies first reported a position in AMLX in Q1 2022 and has held it in 15 quarters since. The position peaked at $6.43M in Q4 2023. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

Cubist Systematic Strategies held 5,603 shares of Amylyx Pharmaceuticals worth $76.1K as of Q3 2025.
Cubist Systematic Strategies sold 117,639 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $1.11M.
Amylyx Pharmaceuticals made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2811 holding.
Cubist Systematic Strategies first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
Cubist Systematic Strategies's Amylyx Pharmaceuticals position peaked at $6.43M in Q4 2023.
169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.